IDentif . AI : Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐Cov‐2) with digital drug development-Reference-Cited by-同舟云学术

IDentif . AI : Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐Cov‐2) with digital drug development

Published:2020-12 Issue:1 Volume:6 Page:
ISSN:2380-6761
Container-title:Bioengineering & Translational Medicine
language:en
Short-container-title:Bioeng Transl Med

Author:

Blasiak Agata¹²³^ORCID,Lim Jhin Jieh⁴,Seah Shirley Gek Kheng⁵,Kee Theodore¹²³^ORCID,Remus Alexandria¹²³^ORCID,Chye De Hoe⁵,Wong Pui San⁵,Hooi Lissa⁴,Truong Anh T. L.¹²³^ORCID,Le Nguyen¹²³^ORCID,Chan Conrad E. Z.⁵,Desai Rishi⁶,Ding Xianting⁷,Hanson Brendon J.⁵,Chow Edward Kai‐Hua¹²³⁴⁸,Ho Dean¹²³⁸^ORCID

Affiliation:

1. The N.1 Institute for Health (N.1) National University of Singapore Singapore Singapore

2. The Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine National University of Singapore Singapore Singapore

3. Department of Biomedical Engineering, NUS Engineering National University of Singapore Singapore Singapore

4. Cancer Science Institute of Singapore National University of Singapore Singapore Singapore

5. Defence Medical and Environmental Research Institute DSO National Laboratories Singapore Singapore

6. Osmosis Baltimore Maryland USA

7. Institute for Personalized Medicine, School of Biomedical Engineering Shanghai Jiao Tong University Shanghai China

8. Department of Pharmacology, Yong Loo Lin School of Medicine National University of Singapore Singapore Singapore

Funder

National Basic Research Program of China

National Research Foundation Singapore

National Natural Science Foundation of China

Micron Foundation

Publisher

Wiley

Subject

Pharmaceutical Science,Biomedical Engineering,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/btm2.10196

Reference60 articles.

1. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

2. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

3. Compassionate Use of Remdesivir for Patients with Severe Covid-19

4. NIH.NIH clinical trial shows Remdesivir accelerates recovery from advanced COVID‐19. NIH.https://www.nih.gov/news-events/news-releases/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19. Accessed 29 Apr 2020

5. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of Broad‐Spectrum Repurposed Drug Combinations Against Carbapenem‐Resistant Enterobacteriaceae (CRE) Through Artificial Intelligence (AI)‐Driven Platform;Advanced Therapeutics;2024-01-18

2. CURATE.AI—Artificial Intelligence‐Derived Personalized Tacrolimus Dosing for Pediatric Liver Transplant: A Retrospective Study;Advanced Therapeutics;2023-12-31

3. The underuse of AI in the health sector: Opportunity costs, success stories, risks and recommendations;Health and Technology;2023-12-12

4. Comparing the Performance of Multiple Small-Data Personalized Tacrolimus Dosing Models for Pediatric Liver Transplant: A Retrospective Study*;2023 45th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC);2023-07-24

5. Artificial intelligence aids in development of nanomedicines for cancer management;Seminars in Cancer Biology;2023-02